APEC - Internationalization of industrial Science and Technology

Emerging Technologies

Not updated for the last 2 years. New version, coming soon!!

Australian Synchrotron will open in 2007. Among other uses, it will provide important capabilities in nanotechnology and microtechnology, facilitating the availability of smart integrated micro-devices for commercialisation in the automotive, aerospace, defence, ICT and biotechnology sectors.
The Commonwealth Scientific and Industrial Research Organisation (CSIRO) capabilities include high performance computing and communication; leading edge ICT solutions; intelligent transport systems, artificial intelligence; and spatial information systems. Doing Business with CSIRO offers industry access to experts and facilities that are at the leading edge of international research. The ICT Centreat CSIRO focuses on four key research areas: Autonomous Systems, Networking Technologies, Information Engineering, and Wireless Technologies.

Zyvex President Tours Australian R&D Centres for Nanotech Gems; Australia, Home to Global Names Such as pSividia, Starpharma, Alchemia, and Bionic Ear Maker Cochlear

SAN FRANCISCO --(Business Wire)-- Sept. 28, 2005 -- Australia, which is fast becoming a world leader in smart nanotech materials such as "invisible" coatings, and revolutionary nanobio technology, has attracted one of the US nanotech leaders to its shores in search of breakthrough technology.

According to Senior Investment Commissioner for North America Robert Hunt: "Zyvex is visiting Australia to acquaint itself first-hand with the nanotechnology market opportunities, as well as to get a more in depth knowledge of a variety of break-through research being conducted at Australian research institutions."
With 370 biotech companies (most of which are SMEs with a single product line) and 600 medical device companies Australia ranks sixth in the world. Market Capitalisation of Australian biotechs on the ASX was US$7.132 billion. Most Australia firms are spin-offs from the research sector. 70% of new firms in 2003 emerged from public research organisations Australian biotech industry employs about 6,000 employed in the sector. Biotech & Healthcare was the lead sector in attracting VC funding in 2003. Government spending on biotech R&D was A$968m and business spending on R&D was $517 million. 70 new US biotech patents were granted in year to March 2004.
Source: Zyvex President Tours Australian R&D Centres for Nanotech Gems

R&D in Biotechnology

	Manufacturing	Wholesale Trade	Property & Business services	Other industries	Total
Number of businesses	69	17	148	18	252
Expenditure on R&D
Total ($ '000)	179264	24934	313213	17041	534452
As a proportion of total BERD	5	9	19	1	7
Human Resources devoted to R&D
Total (person-years)	959	123	1600	112	2794
As a proportion of total human resources	5	6	14	2	7

Note: (a) Only includes R&D performers who had expenditure on biotechnology related R&D. The R&D was performed by themself and/or another.